TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30129045

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (RM) after R-CHOP-based induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP-based induction therapy
Number of subjects: 0
Study: 30130439

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (30 mg/kg IV single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (≤ 150 mg/kg every 3 days, subcutaneous and IV)
Number of subjects: 0
Study: 30131059

Group type: EXPERIMENTAL
Intervention: Inconsistently moderate drinkers (males: 1-168 g ethanol/week; females: 1-112 g ethanol/week)
Number of subjects: 35132

Group type: EXPERIMENTAL
Intervention: Former drinkers
Number of subjects: 35132

Group type: EXPERIMENTAL
Intervention: Consistent non-drinkers
Number of subjects: 35132

Group type: COMPARATOR
Intervention: Consistently heavy drinkers
Number of subjects: 35132

Group type: COMPARATOR
Intervention: Inconsistently heavy drinkers
Number of subjects: 35132
Study: 30131390

Group type: EXPERIMENTAL
Intervention: Post-surgery (after partial pancreatectomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-surgery (before partial pancreatectomy)
Number of subjects: 0
Study: 30131727

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30131748

Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30132694

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clinical observation
Number of subjects: 39
Study: 30132969

Group type: EXPERIMENTAL
Intervention: Higher fetal hemoglobin (HbF) levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin (Hb) concentration
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Composite endpoint of severe clinical events
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hospitalization due to febrile illness
Number of subjects: 57
Study: 30133164

Group type: EXPERIMENTAL
Intervention: Exercise therapy for 12 weeks
Number of subjects: 31
Study: 30134122

Group type: EXPERIMENTAL
Intervention: Purified protein derivative-treated sarcoidosis PBMCs
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control PBMCs
Number of subjects: 11
Study: 30134131

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg) every 3 weeks for up to four doses, followed by Nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nivolumab combined with Ipilimumab
Number of subjects: 94
Study: 30134368

Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in PACD patients
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in primary angle closure suspect (PACS)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in primary angle closure (PAC)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in primary angle closure glaucoma (PACG)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in PACD after matching
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Age-related effects on ATR astigmatism
Number of subjects: 808
Study: 30134969

Group type: EXPERIMENTAL
Intervention: Accepted applications
Number of subjects: 201

Group type: COMPARATOR
Intervention: Not Accepted applications
Number of subjects: 201
Study: 30135031

Group type: COMPARATOR
Intervention: Poor Metabolizers (PM)
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: CYP2C19 groups
Number of subjects: 2558
Study: 30135052

Group type: EXPERIMENTAL
Intervention: HITSystem eHealth intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard EID
Number of subjects: 17
Study: 30135256

Group type: EXPERIMENTAL
Intervention: Normalized digit-span forward (d-sf) scores in participants with nmDMD mutations downstream of exon 30
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Normalized digit-span forward (d-sf) scores in participants with nmDMD mutations downstream of exon 45
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Normalized digit-span forward (d-sf) scores in participants with nmDMD mutations downstream of exon 63
Number of subjects: 169
Study: 30135747

Group type: EXPERIMENTAL
Intervention: Discussion Group (DG)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Minimally Guided (MSG)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 84
Study: 30135755

Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (CCBT) with Internet Support Group (ISG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (CCBT) without Internet Support Group (ISG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional face-to-face psychotherapies
Number of subjects: 0
Study: 30135764

Group type: EXPERIMENTAL
Intervention: Unguided internet-delivered cognitive-behavioral therapy for insomnia (ICBTi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (Cognitive-behavioral therapy for insomnia)
Number of subjects: 0
Study: 30137238

Group type: EXPERIMENTAL
Intervention: TFV disoproxil fumarate (TDF)-based therapy
Number of subjects: 532
Study: 30137350

Group type: EXPERIMENTAL
Intervention: Objectively measured physical activity (PA) levels
Number of subjects: 130
Study: 30137396

Group type: EXPERIMENTAL
Intervention: Weight-for-length z score (zWFL) at birth
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Weight gain from 0 to 2 years
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Childhood adiposity
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment for insulin resistance
Number of subjects: 630
Study: 30137397

Group type: EXPERIMENTAL
Intervention: Adrenal venous sampling (AVS)
Number of subjects: 39
Study: 30137406

Group type: EXPERIMENTAL
Intervention: Higher bioavailable testosterone, free testosterone, dehydroepiandrosterone (DHEA), and lower sex hormone-binding globulin (SHBG) levels
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Higher total testosterone in women
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Higher estradiol in men
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Higher total testosterone, bioavailable testosterone, free testosterone, DHEA, and lower estradiol and SHBG in women longitudinally
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Higher free testosterone and estradiol in men longitudinally
Number of subjects: 2371
Study: 30137477

Group type: EXPERIMENTAL
Intervention: 14-d models
Number of subjects: 7

Group type: COMPARATOR
Intervention: Long-term full models
Number of subjects: 7
Study: 30137523

Group type: EXPERIMENTAL
Intervention: Skeletal muscle transcriptome analysis in Malays
Number of subjects: 156

Group type: COMPARATOR
Intervention: Skeletal muscle transcriptome analysis in Chinese
Number of subjects: 156

Group type: COMPARATOR
Intervention: Skeletal muscle transcriptome analysis in Asian-Indians
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Gene clusters analysis
Number of subjects: 156
Study: 30137527

Group type: EXPERIMENTAL
Intervention: Radioactive iodine (RAI) treatment
Number of subjects: 279
Study: 30137598

Group type: EXPERIMENTAL
Intervention: Maternal knowledge of childhood sleep (measured by Parents' Sleep Knowledge Inventory)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Daily sleep duration and variability measured by wrist actigraphy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CSHQ sleep disturbance scores
Number of subjects: 112
Study: 30138022

Group type: EXPERIMENTAL
Intervention: brief cognitive-behavioral therapy (bCBT)
Number of subjects: 132
Study: 30138170

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) measured noninvasively by multiwavelength pulse co-oximetry
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) trending ability
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prediction of hypoxia (PaO2 <100 mm Hg) using ORi
Number of subjects: 20
Study: 30138228

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (12-week duration)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Typical walking
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Challenging walking tasks (obstacles and dual-task walking)
Number of subjects: 31
Study: 30138394

Group type: EXPERIMENTAL
Intervention: Combined copeptin/cTN testing
Number of subjects: 713

Group type: COMPARATOR
Intervention: Serial cTN testing
Number of subjects: 713
Study: 30138550

Group type: EXPERIMENTAL
Intervention: MAP2K1-positive melorheostosis patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Affected bone from MAP2K1-positive patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: MAP2K1-negative patients
Number of subjects: 15
Study: 30138687

Group type: EXPERIMENTAL
Intervention: Liver biopsy and transient elastography
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Presence of metabolic syndrome
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Transient elastography
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Accumulated abnormal AAT in hepatocytes, portal inflammation, and hepatocellular degeneration
Number of subjects: 94
Study: 30138736

Group type: EXPERIMENTAL
Intervention: NCGWS patients
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-NCGWS controls
Number of subjects: 78
Study: 30138764

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus pemetrexed-carboplatin (PC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: PC alone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus PC
Number of subjects: 123
Study: 30138841

Group type: EXPERIMENTAL
Intervention: General reproductive health visits with both current and past elevated depressive symptoms
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Abortion patients with current elevated depressive symptoms
Number of subjects: 1215
Study: 30139013

Group type: EXPERIMENTAL
Intervention: Moderate/severe obstructive sleep apnea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no obstructive sleep apnea)
Number of subjects: 0
Study: 30139368

Group type: EXPERIMENTAL
Intervention: Preconditioning strategies for mesenchymal stem cells (MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30139372

Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ) administered orally for 5 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo administered orally for 5 days
Number of subjects: 66
Study: 30139707

Group type: EXPERIMENTAL
Intervention: Proactive smoking-cessation intervention
Number of subjects: 5123

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5123
Study: 30139779

Group type: EXPERIMENTAL
Intervention: CXCR2 antagonist danirixin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30139840

Group type: EXPERIMENTAL
Intervention: Linsitinib 450 mg daily on days 1-3 every 7 days and irinotecan 125 mg/m²
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Linsitinib 400 mg and irinotecan 100 mg/m²
Number of subjects: 17
Study: 30139897

Group type: EXPERIMENTAL
Intervention: Medication intake
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Well-being
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 50

Group type: COMPARATOR
Intervention: Symptoms (dizziness, headache, restlessness, fatigue, palpitations)
Number of subjects: 50
Study: 30139899

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) during general anaesthesia for robotic-assisted surgery (RAS)
Number of subjects: 0
Study: 30139903

Group type: EXPERIMENTAL
Intervention: MK-7 (720 µg/day) supplemented by vitamin D (25 µg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo treatment (no active treatment)
Number of subjects: 400
Study: 30140207

Group type: EXPERIMENTAL
Intervention: Excitatory Repetitive Transcranial Magnetic Stimulation (eTMS)
Number of subjects: 0
Study: 30140582

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 592
Study: 30140912

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30141830

Group type: EXPERIMENTAL
Intervention: Quitting competitive swimming
Number of subjects: 0
Study: 30142084

Group type: EXPERIMENTAL
Intervention: 12 week supervised exercise therapy alone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy alone
Number of subjects: 140
Study: 30142422

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) - specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and fish oil (FO)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of fish oil (FO) and cytarabine (AraC)
Number of subjects: 5
Study: 30142751

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 4136

Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB)
Number of subjects: 4136

Group type: EXPERIMENTAL
Intervention: LUTS presence
Number of subjects: 4136

Group type: EXPERIMENTAL
Intervention: Healthcare visits for urinary symptoms
Number of subjects: 4136
Study: 30143019

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 128
Study: 30143031

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 42
Study: 30143412

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence in individuals with CD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary habits of individuals with CD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary habits of healthy participants
Number of subjects: 0
Study: 30143448

Group type: EXPERIMENTAL
Intervention: Kardia Mobile Cardiac Monitor (KMCM) automated algorithm
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Physician-interpreted KMCM recordings
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Physician interpretation of KMCM recordings
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unclassified recordings by KMCM algorithm
Number of subjects: 52
Study: 30143454

Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 42
Study: 30143455

Group type: EXPERIMENTAL
Intervention: HIV care linkage
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Retention in care after starting ART
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Viral load testing
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Loss to follow-up after starting treatment
Number of subjects: 831

Group type: COMPARATOR
Intervention: Treatment initiation likelihood based on site type
Number of subjects: 831

Group type: COMPARATOR
Intervention: Viral suppression likelihood based on education level
Number of subjects: 831
Study: 30143474

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.2 (THS 2.2)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Continued smoking of combustible cigarettes
Number of subjects: 984
Study: 30143477

Group type: EXPERIMENTAL
Intervention: Active Coach app combined with Fitbit activity tracker (n=60)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Print-based generic physical activity information (Control group)
Number of subjects: 130
Study: 30144299

Group type: EXPERIMENTAL
Intervention: Achieving minimal disease activity (MDA) at 12 months
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sustained minimal disease activity (sMDA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: MDA group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-MDA group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MDA maintenance
Number of subjects: 101
Study: 30144422

Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine
Number of subjects: 222
Study: 30144803

Group type: EXPERIMENTAL
Intervention: non-HDL-C
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: TC/HDL
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: non-HDL-C, TC/HDL, TG/HDL, LDL/HDL
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Individual lipid parameters (TC, TG, LDL-C, HDL-C)
Number of subjects: 1599
Study: 30144818

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB) guided by ultrasound or mammography
Number of subjects: 600
Study: 30144981

Group type: EXPERIMENTAL
Intervention: FIRM ablation with PVAI
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation
Number of subjects: 0
Study: 30145030

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 30145316

Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurements in EoE patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mucosal impedance (MI) measurements in control subjects
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of eosinophils per high-power field (eos/HPF) with minimum MI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of eosinophils per high-power field (eos/HPF) with average MI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of endoscopic reference score with minimum MI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of endoscopic reference score with average MI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Abnormal MI segments in inactive EoE patients
Number of subjects: 33
Study: 30145340

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory systolic BP
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Clinic systolic BP
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Supine-to-sit time (mobility measure)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cognitive measures (Trails Making Test Part A and the Stroop Word Test)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Home systolic BP
Number of subjects: 199
Study: 30146701

Group type: EXPERIMENTAL
Intervention: ZX008 (fenfluramine HCl) at an initial dose of 0.2 mg/kg/d, with escalations up to 0.8 mg/kg/d or 30 mg/d every 4 weeks in nonresponders.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ZX008 (fenfluramine HCl) continued in long-term extension study after 20 weeks.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Adverse events related to ZX008 treatment.
Number of subjects: 13
Study: 30148443

Group type: EXPERIMENTAL
Intervention: Broad informed consent (IC)
Number of subjects: 146
Study: 30148996

Group type: EXPERIMENTAL
Intervention: SULCS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: AMAT
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: BBT
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: FMA
Number of subjects: 61
Study: 30149145

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (canagliflozin)
Number of subjects: 3667

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (dapagliflozin)
Number of subjects: 3667

Group type: EXPERIMENTAL
Intervention: Incretin agents (liraglutide)
Number of subjects: 3667

Group type: EXPERIMENTAL
Intervention: Incretin agents (sitagliptin)
Number of subjects: 3667

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 3667
Study: 30149823

Group type: EXPERIMENTAL
Intervention: Increased intakes of vegetables, fruit, and milk
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Changes in food intake patterns
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Contribution of cooked staple porridges and bread made from fortified maize and bread flour
Number of subjects: 2010
Study: 30150316

Group type: EXPERIMENTAL
Intervention: cfDNA-Seq technology using 25 ng of cfDNA
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: cfDNA-Seq technology
Number of subjects: 58
Study: 30151192

Group type: EXPERIMENTAL
Intervention: Standard operating procedures for managing patients with NTM respiratory infections
Number of subjects: 0
Study: 30151972

Group type: EXPERIMENTAL
Intervention: Marzeptacog alfa (activated) at intravenous doses up to 30 μg kg
Number of subjects: 0
Study: 30152164

Group type: EXPERIMENTAL
Intervention: Hybrid cognitive-behavioral therapy intervention
Number of subjects: 21
Study: 30152888

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid vasopressin (AVP) concentration in children with autism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid vasopressin (AVP) concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30153037

Group type: EXPERIMENTAL
Intervention: Screen time
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Severe obesity
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 817
Study: 30153046

Group type: COMPARATOR
Intervention: Mothers without asthma and without preeclampsia
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Mothers without asthma with preeclampsia
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Mothers with asthma without preeclampsia
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Mothers with asthma with preeclampsia
Number of subjects: 806
Study: 30153232

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (single intravenous dose, age-based)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (single intravenous dose)
Number of subjects: 37
Study: 30153529

Group type: EXPERIMENTAL
Intervention: Growth hormone deficiency (GHD) patients after aerobic exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sedentary male control subjects (CS) after aerobic exercise
Number of subjects: 14
Study: 30153638

Group type: EXPERIMENTAL
Intervention: Recurrent suicide attempts (SA)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Psychiatric hospitalization
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Sedative use disorders
Number of subjects: 433